Literature DB >> 16045490

Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats.

Devi Rani Sagar1, Sara Kelly, Paul J Millns, Celestine T O'Shaughnessey, David A Kendall, Victoria Chapman.   

Abstract

Cannabinoid 2 (CB2) receptor mediated antinociception and increased levels of spinal CB2 receptor mRNA are reported in neuropathic Sprague-Dawley rats. The aim of this study was to provide functional evidence for a role of peripheral, vs. spinal, CB2 and cannabinoid 1 (CB1) receptors in neuropathic rats. Effects of the CB2 receptor agonist, JWH-133, and the CB1 receptor agonist, arachidonyl-2-chloroethylamide (ACEA), on primary afferent fibres were determined by calcium imaging studies of adult dorsal root ganglion (DRG) neurons taken from neuropathic and sham-operated rats. Capsaicin (100 nm) increased [Ca2+]i in DRG neurons from sham and neuropathic rats. JWH-133 (3 microm) or ACEA (1 microm) significantly (P<0.001) attenuated capsaicin-evoked calcium responses in DRG neurons in neuropathic and sham-operated rats. The CB2 receptor antagonist, SR144528, (1 microm) significantly inhibited the effects of JWH-133. Effects of ACEA were significantly inhibited by the CB1 receptor antagonist SR141716A (1 microm). In vivo experiments evaluated the effects of spinal administration of JWH-133 (8-486 ng/50 microL) and ACEA (0.005-500 ng/50 microL) on mechanically evoked responses of neuropathic and sham-operated rats. Spinal JWH-133 attenuated mechanically evoked responses of spinal neurons in neuropathic, but not sham-operated rats. These inhibitory effects were blocked by SR144528 (0.001 microg/50 microL). Spinal ACEA inhibited mechanically evoked responses of neuropathic and sham-operated rats, these effects were blocked by SR141716A (0.01 microg/50 microL). Our data provide evidence for a functional role of CB2, as well as CB1 receptors on DRG neurons in sham and neuropathic rats. At the level of the spinal cord, CB2 receptors have inhibitory effects in neuropathic, but not sham-operated rats suggesting that spinal CB2 may be an important analgesic target.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16045490     DOI: 10.1111/j.1460-9568.2005.04206.x

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  62 in total

1.  Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice.

Authors:  Hai-Ying Zhang; Ming Gao; Qing-Rong Liu; Guo-Hua Bi; Xia Li; Hong-Ju Yang; Eliot L Gardner; Jie Wu; Zheng-Xiong Xi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-03       Impact factor: 11.205

2.  Reduction of bone cancer pain by CB1 activation and TRPV1 inhibition.

Authors:  Tomoyuki Kawamata; Yukitoshi Niiyama; Jun Yamamoto; Shingo Furuse
Journal:  J Anesth       Date:  2010-04-07       Impact factor: 2.078

Review 3.  CB2: a cannabinoid receptor with an identity crisis.

Authors:  Brady K Atwood; Ken Mackie
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

4.  A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss.

Authors:  Alysia N Lozano-Ondoua; Courtney Wright; Anna Vardanyan; Tamara King; Tally M Largent-Milnes; Mark Nelson; Juan Miguel Jimenez-Andrade; Patrick W Mantyh; Todd W Vanderah
Journal:  Life Sci       Date:  2010-02-20       Impact factor: 5.037

5.  Continuous infusion of the cannabinoid WIN 55,212-2 to the site of a peripheral nerve injury reduces mechanical and cold hypersensitivity.

Authors:  I J Lever; T M Pheby; A S C Rice
Journal:  Br J Pharmacol       Date:  2007-03-20       Impact factor: 8.739

6.  In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models.

Authors:  B B Yao; G C Hsieh; J M Frost; Y Fan; T R Garrison; A V Daza; G K Grayson; C Z Zhu; M Pai; P Chandran; A K Salyers; E J Wensink; P Honore; J P Sullivan; M J Dart; M D Meyer
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

7.  Characterisation of cannabinoid 1 receptor expression in the perikarya, and peripheral and spinal processes of primary sensory neurons.

Authors:  Gabor Veress; Zoltan Meszar; Dora Muszil; Antonio Avelino; Klara Matesz; Ken Mackie; Istvan Nagy
Journal:  Brain Struct Funct       Date:  2012-05-22       Impact factor: 3.270

8.  Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.

Authors:  Liting Deng; Josée Guindon; Benjamin L Cornett; Alexandros Makriyannis; Ken Mackie; Andrea G Hohmann
Journal:  Biol Psychiatry       Date:  2014-04-25       Impact factor: 13.382

9.  Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats.

Authors:  E J Rahn; A Makriyannis; A G Hohmann
Journal:  Br J Pharmacol       Date:  2007-06-18       Impact factor: 8.739

Review 10.  Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain.

Authors:  J Guindon; A G Hohmann
Journal:  Br J Pharmacol       Date:  2007-11-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.